

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

<i>Application Number</i>	10/742,346
<i>Filing Date</i>	December 19, 2003
<i>First Named Inventor</i>	Falotico
<i>Group Art Unit</i>	1615
<i>Examiner Name</i>	C. AZPURU
<i>Attorney Docket Number</i>	CRD5062USNP/Conf. No. 6421

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BERK, et al. "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty", JACC, Vol. 17, No. 6, May 1991 pp. 111B-117B	
		CHANG, et al. "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty", U. of Chicago, Department of Medicine and Pathology, Volume 96, Nov. 1995, Vol. 96, pp. 2260-2268	
		CLOWES, et al., "Suppression by Heparin of Smooth Muscle Cell Proliferation in Injured Arteries", Nature, Vol. 265, Feb. 1977, pp. 625-626	
		CLOWES, et al., "Kinetics of Cellular Proliferation After Arterial Injury", Circulation Research, Vol. 58, No. 6, June 1986, pp. 839-845	
		FABR, et al., "Vascular Smooth Muscle Cell Cytotoxicity and Sustained inhibition of Neointimal Formation by Fibroblast Growth Factor 2-Saporin Fusion Protein", Circulation Research Vol. 80, No. 4, April 1997, pp. 542-550	
		FERNS, et al. "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGE", Science, Vol. 254, Sept. 1991, pp. 1129-1132	
		Fukuyama, et al., "Tranilast Suppresses the Vascular Intimal Hyperplasia After Balloon Injury in Rabbits Fed on a High-Cholesterol Diet", European Journal of Pharmacology, 318, 1996, pp. 327-332	
		GUYTON, et al., "Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin", Circulation Research, Vol. 46, No. 5, May 1980, pp. 625-633	
		Hansson, et al., "Interferon-γ Inhibits Arterial Stenosis After Injury", 1991, Vol. 84, pp. 1266-1272	
		JONASSSSON, et al, "Cycloporin A Inhibits Smooth Muscle Proliferation in the Vascular Response to Injury", Proc. Acad., Sci. 1988, Vol. 85, pp. 2303-2306	
		LIU, et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the atherosclerotic Rabbit", Circl. 1990, Vol. 81, No. 3, pp. 1089-1093	
		LUNDERGAN, et al, "Peptide Inhibition of Myointimal Proliferation by Angiopeptin, a Samatostatin Analogue", JAC, Vol. 17, No. 6, May 1991, p. 132B-136B	
		MAJESKY, et al., Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery", Circulation Res. 1987, Vol. 61, pp. 296-300	
		MARX, et al., Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells", Circ Research, 1995, Vol. 76, No. 3, pp. 412-417	
		NEMECEK, et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor In Vitro and Neointimal Proliferation in Vivo", JPET, 1989, Vol. 248, No. 3, pp. 1167-1174	
		Okada, et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury Without Systemic Anticoagulation", Neurosurgery, 1989, Vol. 25, No. 6, p. 892-898	
		POWELL, et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury", Science, Vol. 243, 1989, pp. 186-188	
		SIMONS, et al., "Antisense c-myb oligonucleotides Inhibit Intimal Arterial Smooth Muscle Cell Accumulation in vivo", Nature, 1992, Vol. 359, pp. 67-70	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 3		<i>Application Number</i>	10/742,346
		<i>Filing Date</i>	December 19, 2003
		<i>First Named Inventor</i>	Falotico
		<i>Group Art Unit</i>	1615
		<i>Examiner Name</i>	C. Azpuru
		<i>Attorney Docket Number</i>	CRD5062USN/Conf. No. 6421
		SNOW, et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", American J. of Pathology, Vol. 137, No. 2, 1990, pp. 313-330	
		SOLLOTT, et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", Journal of Clinical Investigation, Inc., Vol. 95, 1995, pp. 1869-1876	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 3

Confirmation Number	6421
Application Number	10/742,346
Filing Date	December 19, 2003
First Named Inventor	Falotico
Group Art Unit	1615
Examiner Name	C. Azpuru
Attorney Docket Number	CRD5062USNP

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).
- OR**
- ☒ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).
- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

STATEMENT

This is supplement to the Information Disclosure Statements filed May 20, 2005 and August 13, 2007.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Carl J. Evens/	Date (YYYY-MM-DD)	2007-09-05
Name/Print	Carl J. Evens	Registration Number	33,874

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**